AI Engines For more Details: Perplexity Kagi Labs You
Local Anesthesia: Propoxycaine hydrochloride works by blocking nerve signals in a specific area of the body, resulting in temporary loss of sensation. It is commonly used for procedures such as dental work, minor surgeries, and dermatological procedures.
Short-Acting: Propoxycaine hydrochloride is a short-acting local anesthetic, meaning its effects wear off relatively quickly compared to other local anesthetics. This property makes it suitable for brief procedures or when rapid onset and recovery of anesthesia are desired.
Low Systemic Toxicity: When used as directed, propoxycaine hydrochloride typically has low systemic toxicity, meaning it has minimal effects on other parts of the body beyond the area where it is applied. However, like all local anesthetics, it can potentially cause adverse reactions if absorbed into the bloodstream in excessive amounts.
Side Effects: Common side effects associated with the use of propoxycaine hydrochloride may include temporary numbness, tingling, or burning sensation at the site of administration. Rarely, allergic reactions such as rash, itching, or swelling may occur.
Systemic Toxicity: While rare, systemic toxicity can occur if propoxycaine hydrochloride is inadvertently injected into a blood vessel or absorbed in large amounts. Symptoms of systemic toxicity may include dizziness, confusion, seizures, respiratory depression, and cardiovascular collapse. Prompt recognition and treatment of systemic toxicity are essential to prevent serious complications.
Drug Interactions: Propoxycaine hydrochloride may interact with certain medications, such as other local anesthetics or medications that affect the cardiovascular system, increasing the risk of adverse effects. Healthcare providers should be aware of potential drug interactions and adjust dosages accordingly.
Pregnancy and Breastfeeding: The safety of propoxycaine hydrochloride use during pregnancy and breastfeeding has not been well established. Healthcare providers should weigh the potential risks and benefits before administering propoxycaine hydrochloride to pregnant or breastfeeding individuals.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.3 | 0.3 | 0 |
| Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.2 | -1 |
| Allergic Rhinitis (Hay Fever) | 0.2 | 0.2 | |
| Allergies | 0 | 0.1 | 0 |
| Allergy to milk products | 0 | 0.2 | 0 |
| Alzheimer's disease | 0 | 0.4 | 0 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0 | 0 |
| Ankylosing spondylitis | 0 | 0 | |
| Anorexia Nervosa | 0.2 | 0.1 | 1 |
| Antiphospholipid syndrome (APS) | 0.2 | 0.2 | |
| Asthma | 0 | 0.1 | 0 |
| Atherosclerosis | 0 | 0.2 | 0 |
| Atrial fibrillation | 0.5 | 0.2 | 1.5 |
| Autism | 0.6 | 0.6 | 0 |
| Bipolar Disorder | 0.2 | 0.5 | -1.5 |
| Brain Trauma | 0.1 | -0.1 | |
| Carcinoma | 0.2 | 0.2 | 0 |
| Celiac Disease | 0.2 | -0.2 | |
| Cerebral Palsy | 0.1 | -0.1 | |
| Chronic Fatigue Syndrome | 0.5 | 1.3 | -1.6 |
| Chronic Kidney Disease | 0.2 | 0.4 | -1 |
| Chronic Lyme | 0.1 | -0.1 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | -0.4 | |
| Coagulation / Micro clot triggering bacteria | 0.2 | 0.1 | 1 |
| Colorectal Cancer | 0.3 | 0.3 | |
| Constipation | 0.1 | -0.1 | |
| Coronary artery disease | 0 | 0.3 | 0 |
| COVID-19 | 0.6 | 0.7 | -0.17 |
| Crohn's Disease | 0.6 | 0.6 | 0 |
| cystic fibrosis | 0.1 | -0.1 | |
| deep vein thrombosis | 0.1 | -0.1 | |
| Depression | 1.2 | 2.1 | -0.75 |
| Endometriosis | 0.5 | 0 | 0 |
| Epilepsy | 0.5 | -0.5 | |
| Fibromyalgia | 0.5 | 0.7 | -0.4 |
| Functional constipation / chronic idiopathic constipation | 0.3 | 0.4 | -0.33 |
| gallstone disease (gsd) | 0.2 | 0.1 | 1 |
| Generalized anxiety disorder | 0.3 | -0.3 | |
| Gout | 0.3 | -0.3 | |
| Graves' disease | 0.2 | 0.1 | 1 |
| Hashimoto's thyroiditis | 0.1 | 0.1 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.1 | 0.1 | |
| hyperglycemia | 0.2 | -0.2 | |
| hypertension (High Blood Pressure | 0.2 | 0.4 | -1 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 0.2 | 0.2 | |
| Inflammatory Bowel Disease | 0 | 0.7 | 0 |
| Insomnia | 0.1 | -0.1 | |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.2 | 0.2 | |
| Irritable Bowel Syndrome | 0.1 | 0.2 | -1 |
| Liver Cirrhosis | 0.6 | 0.4 | 0.5 |
| Long COVID | 0.8 | 0.7 | 0.14 |
| Low bone mineral density | 0.4 | -0.4 | |
| Lung Cancer | 0 | 0 | |
| ME/CFS with IBS | 0.7 | -0.7 | |
| ME/CFS without IBS | 0.2 | 0.2 | |
| Metabolic Syndrome | 0.6 | 0.6 | 0 |
| Mood Disorders | 1.6 | 2.2 | -0.38 |
| Multiple Sclerosis | 0.3 | 0.3 | 0 |
| Multiple system atrophy (MSA) | 0 | 0 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.4 | -0.4 | |
| Obesity | 0.6 | 1.1 | -0.83 |
| obsessive-compulsive disorder | 0.2 | 0.3 | -0.5 |
| Osteoarthritis | 0 | 0 | |
| Osteoporosis | 0.1 | 0.1 | |
| Parkinson's Disease | 0.5 | 0.6 | -0.2 |
| Polycystic ovary syndrome | 0.2 | 0.2 | 0 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.2 | -0.2 | |
| Psoriasis | 0 | 0.6 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.6 | 0.4 | 0.5 |
| Rosacea | 0 | 0.1 | 0 |
| Schizophrenia | 0.5 | 0.4 | 0.25 |
| scoliosis | 0.3 | 0 | 0 |
| Sjögren syndrome | 0.2 | 0.2 | 0 |
| Sleep Apnea | 0.4 | 0.4 | 0 |
| Stress / posttraumatic stress disorder | 0.2 | 0.4 | -1 |
| Systemic Lupus Erythematosus | 0.5 | 0.1 | 4 |
| Tic Disorder | 0 | 0 | |
| Type 1 Diabetes | 0.4 | 0.1 | 3 |
| Type 2 Diabetes | 0.6 | 0.6 | 0 |
| Ulcerative colitis | 0.3 | 0.6 | -1 |
| Unhealthy Ageing | 0.3 | 0.4 | -0.33 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.